Cover Image

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis

Aim: The effect of sacubitril-valsartan (ARNI) in heart failure (HF) patients with mid-range ejection fractions (HFmrEF) remains unclear. This study aimed to investigate the effects of ARNI in HFmrEF patients.Methods: From inception to 15 February 2022, articles were searched via PubMed, Embase, Coc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jianbin Qin (Author), Weijian Wang (Author), Ping Wei (Author), Ping Huang (Author), Ruizhen Lin (Author), Jinming Yue (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
by: Koichiro Matsumura MD, et al.
Published: (2023)

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
by: Po-Lin Lin MD, et al.
Published: (2022)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018)

Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population
by: N. T. Vatutin, et al.
Published: (2021)

Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
by: Giuseppe Armentaro, et al.
Published: (2021)

The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
by: Rui Zhang MD, PhD, et al.
Published: (2022)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
by: Cuthbert JJ, et al.
Published: (2020)

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
by: Mustafa Doğduş, et al.
Published: (2021)

Comparison of clinical features and conventional echocardiographic characteristics of patients with heart failure with mid-range ejection fraction with and without interatrial block
by: Ali Çoner
Published: (2021)

Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial
by: Mohammed Habib
Published: (2018)

Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review
by: Bartosz Sadłowski, et al.
Published: (2024)

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia
by: Zakiyah N, et al.
Published: (2021)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
by: Vilela-Martin JF
Published: (2016)

Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan
by: Lena Holmlund, et al.
Published: (2020)

Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure
by: Sara Mucherino, et al.
Published: (2023)

Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
by: Elodie Charuel, et al.
Published: (2021)

Prognostic of NT-proBNP in heart failure patients with preserved, mid and reduced ejection fraction
by: Reynie Leonel Reinoso Gonella, et al.
Published: (2021)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
by: Yue Wu, et al.
Published: (2020)

Natriuretic peptide pathways in heart failure in the context of the analysis of the mechanism of action and potential usages of sacubitril/valsartan
by: Kamila Babkiewicz-Jahn, et al.
Published: (2024)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
by: Velia Cassano, et al.
Published: (2022)

An Evaluation of the Initiation and Use of Sacubitril/Valsartan in an Inpatient Heart Failure Population: A Retrospective Medication Use Evaluation
by: Tara Snyder, et al.
Published: (2019)

Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
by: T. V. Ashcheulova, et al.
Published: (2019)

Comparison of the Efficacy and Safety of Sacubitril/Valsartan and Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients With Reduced Ejection Fraction Combined With Moderate-to-Severe Chronic Kidney Disease
by: Zhaowei Zhang MD, et al.
Published: (2024)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022)

Sacubitril/valsartan in real-life clinical practice
by: Yüksel Çavuşoğlu
Published: (2021)

Sacubitril-valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
by: Tianyang Hu, et al.
Published: (2023)

Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
by: Shih-Hsing Lo, et al.
Published: (2021)

Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register
by: Björn Eriksson, et al.
Published: (2019)

Plasma digoxin levels and ejection fraction in pediatric heart failure
by: Nafrialdi Nafrialdi, et al.
Published: (2016)

New to paradigm for the treatment of heart failure with reduced ejection fraction?
by: Delfín Rodríguez Leyva
Published: (2015)

Pediatric heart failure with preserved ejection fraction, a review
by: Sophie Quennelle, et al.
Published: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018)

Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis
by: Zhu Chen, et al.
Published: (2022)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
by: James P. Teuber, et al.
Published: (2022)

Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
by: A. A. Shchendrygina, et al.
Published: (2021)

Pediatric heart failure classification based on left ventricular ejection fraction
by: Shan Huang, et al.
Published: (2023)

Role of ARNI upgraded in treatment of heart failure with reduced ejection fraction
by: Swetha Amaresh Biradar
Published: (2021)

Heart failure with preserved ejection fraction (HFpEF): Implications for the anesthesiologists
by: Ajmer Singh, et al.
Published: (2018)